Cardiovascular Research

Rapamycin Prolongs Graft Survival and Induces CD4+IFN-γ+IL-10+ Regulatory Type 1 Cells in Old Recipient Mice.

Authors: Markus Quante|||Timm Heinbokel|||Karoline Edtinger|||Koichiro Minami|||Hirofumi Uehara|||Yeqi Nian|||Haruhito Azuma|||Reza Abdi|||Abdallah Elkhal|||Stefan G Tullius

Affiliations: + Expand

Abstract

Although the elderly represents a rapidly growing population among transplant recipients, age-specific aspects have not been considered sufficiently in clinical trials. Moreover, age-specific effects of immunosuppressive therapies remain poorly understood.

---

Chemical List

Immunosuppressive Agents|||Interleukin-10|||Interferon-gamma|||Sirolimus

---

Reference List

US Department of Health and Human Services Human Respirces and Services Administration. OPTN/SRTR 2012 Annual Data Report. https://srtr.transplant.hrsa.gov/annual_reports/2012/pdf/2012_SRTR_ADR.pdf. Published June 2014.|||Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant. 2010;10(4 Pt 2):961–972.|||Heinbokel T, Elkhal A, Liu G, Edtinger K, Tullius SG. Immunosenescence and organ transplantation. Transplant Rev (Orlando) 2013;27(3):65–75.|||Karim A, Farrugia D, Cheshire J, et al. Recipient age and risk for mortality after kidney transplantation in England. Transplantation. 2014;97(8):832–838.|||Bradley BA. Rejection and recipient age. Transpl Immunol. 2002;10(2-3):125–132.|||Taylor AL, Watson CJE, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56(1):23–46.|||Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev. 2006;127(3):274–281.|||Murasko DM, Weiner P, Kaye D. Decline in mitogen induced proliferation of lymphocytes with increasing age. Clin Exp Immunol. 1987;70(2):440–448.|||Bernstein ED, Murasko DM. Effect of age on cytokine production in humans. Age (Omaha) 1998;21(4):137–151.|||Tullius SG, Tran H, Guleria I, Malek SK, Tilney NL, Milford E. The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. Ann Surg. 2010;252(4):662–674.|||Blosser CD, Huverserian A, Bloom RD, et al. Age, exclusion criteria, and generalizability of randomized trials enrolling kidney transplant recipients. Transplantation. 2011;91(8):858–863.|||U.S. Government Accountability Office. Prescription drugs: FDA guidance and regulations related to data on elderly persons in clinical drug trials. http://www.gao.gov/assets/100/95182.pdf. Published September 28, 2007.|||Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009;9(5):324–337.|||Krenzien F, Quante M, Heinbokel T, et al. Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. Am J Transplant. 2017;17(5):1242–1254.|||Denecke C, Bedi DS, Ge X, et al. Prolonged graft survival in older recipient mice is determined by impaired effector T-cell but intact regulatory T-cell responses. PLoS One. 2010;5(2):e9232.|||Bedi DS, Krenzien F, Quante M, et al. Defective CD8 signaling pathways delay rejection in older recipients. Transplantation. 2016;100(1):69–79.|||Appay V, Sauce D. Naive T cells: the crux of cellular immune aging? Exp Gerontol. 2014;54:90–93.|||Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2010;28:445–489.|||Gagliani N, Magnani CF, Huber S, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. 2013;19(6):739–746.|||Elkhal A, Rodriguez Cetina Biefer H, Heinbokel T, et al. NAD(+) regulates Treg cell fate and promotes allograft survival via a systemic IL-10 production that is CD4(+) CD25(+) Foxp3(+) T cells independent. Sci Rep. 2016;6:22325.|||Zeng H, Zhang R, Jin B, Chen L. Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance. Cell Mol Immunol. 2015;12(5):566–571.|||Tullius SG, Milford E. Kidney allocation and the aging immune response. N Engl J Med. 2011;364(14):1369–1370.|||Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80(7):883–889.|||Singh M, Jensen MD, Lerman A, et al. Effect of Low-Dose Rapamycin on Senescence Markers and Physical Functioning in Older Adults with Coronary Artery Disease: Results of a Pilot Study. J frailty aging. 2016;5(4):204–207.|||Kim YC, Guan KL, Laplante M, et al. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015;125(1):25–32.|||Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009 Jul;|||Ehninger D, Neff F, Xie K. Longevity, aging and rapamycin. Cell Mol Life Sci. 2014;71(22):4325–4346.|||Foldenauer MEB, McClellan SA, Berger EA, Hazlett LD. Mammalian target of rapamycin regulates IL-10 and resistance to pseudomonas aeruginosa corneal infection. J Immunol. 2013;190(11):5649–5658.|||Lim DG, Joe IY, Park YH, et al. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells. Transpl Immunol. 2007;18(2):94–100.|||Battaglia M, Stabilini A, Draghici E, et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes. 2006;55(1):40–49.|||Lu L, Qian XF, Rao JH, Wang XH, Zheng SG, Zhang F. Rapamycin Promotes the Expansion of CD4+ Foxp3+ Regulatory T Cells After Liver Transplantation. Transplant Proc. 2010;42(5):1755–1757.|||Valmori D, Tosello V, Souleimanian NE, et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol. 2006;177(2):944–949.|||Petrelli A, Tresoldi E, Mfarrej BG, et al. Generation of donor-specific T regulatory type 1 cells from patients on dialysis for cell therapy after kidney transplantation. Transplantation. 2015;99(8):1582–1589.|||Hobbs MV, Weigle WO, Ernst DN. Interleukin-10 production by splenic CD4+ cells and cell subsets from young and old mice. Cell Immunol. 1994;154(1):264–272.|||Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75(2):263–274.|||Tullius SG, Biefer HRC, Li S, et al. NAD+ protects against EAE by regulating CD4+ T-cell differentiation. Nat Commun. 2014;5:5101.|||Marlow GJ. Why interleukin-10 supplementation does not work in Crohn's disease patients. World J Gastroenterol. 2013;19(25):3931.